The Recombinant Human (EGF) Market is estimated to be valued at US$ 10,251.1 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

The Recombinant Human (EGF) Market is estimated to be valued at US$ 10,251.1 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Recombinant human epidermal growth factor (rhEGF) are proteins that are mainly used in wound healing applications. They regulate cell growth and differentiation by binding to EGF cell surface receptors. Advantages of rhEGF over endogenous EGF include easy availability, low batch-to-batch variations, and defined purity.

Market key trends:
The recombinant human EGF market is witnessing growth owing to rising investments in biotechnology sector. Rising prevalence of chronic wounds such as diabetic foot ulcers, pressure ulcers, and venous ulcers is also propelling market growth. According to the Wound Care Market Report published by Smith & Nephew, globally around 6.5 million patients suffer from chronic wounds each year. Ease of administering rhEGF coupled with rising awareness about benefits of advanced wound care therapies is further augmenting the demand for EGF in wounds treatment. Increasing number of clinical trials investigating efficacy of rhEGF in different therapeutic areas is also expected to open new avenues for market players over the forecast period.

Porter’s Analysis

Threat of new entrants: The Recombinant Human (EGF) Market already has major key players operating in it along with high R&D and manufacturing costs required to produce these products. This poses moderate threat of new entrants.

Bargaining power of buyers: The bargaining power of buyers is moderate as there are several established brands providing quality products at competitive prices leaving limited scope for further price negotiations.

Bargaining power of suppliers: Due to availability of different raw material suppliers, the bargaining power of suppliers is low in this market.

Threat of new substitutes: There are limited substitutes available for recombinant human (EGF) products.

Competitive rivalry: The rivalry among existing competitors in the market is high due to their global presence and wide product portfolio.

SWOT Analysis

Strength: The global Recombinant Human (EGF) Market has growing applications in wound healing, cancer treatment and drug discovery research with increasing R&D activities.

Weakness: High costs associated with production and purification of recombinant proteins limit their use especially in emerging economies. Stringent regulatory approvals also delay new product launches.

Opportunity: Increasing research on tissue engineering and regenerative medicine is creating new opportunities. Growing biopharmaceutical industryespecially in Asia is also fostering market growth.

Threats: Threat from alternatives like plant and animal derived growth factors and intensity of competitionfrom major players are key threats.

Key Takeaways

The global Recombinant Human (EGF) Market is expected to witness high growth, exhibiting CAGR of 9.3% over the forecast period, due to increasing research in regenerative medicine and stem cell therapy. Growing demand for therapeutic proteins is also boosting market revenues.

Regionally, North America dominates the global recombinant human EGF market accounting for over 35% share in 2023 owing to rising incidents of chronic diseases and strong government support for research activities in the US and Canada. Asia Pacific is projected to exhibit fastest growth owing to expansion of biotech and pharmaceutical sectors in China, India and South Korea.

Key players operating in the Recombinant Human (EGF) Market are Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.